For patients with brain cancer, radiation is a powerful and potentially life-saving treatment, but it can also cause considerable and even permanent injury to the brain. Now, through preclinical experiments conducted in rats, Memorial Sloan Kettering Cancer Center researchers have developed a method to turn human stem cells into cells that are instructed to repair damage in the brain. Rats treated with the human cells regained cognitive and motor functions that were lost after brain irradiation. The findings are reported in the February 5 issue of the journal Cell Stem Cell.

During radiation therapy for brain cancer, progenitor cells that later mature to produce the protective myelin coating around neurons are lost or significantly depleted, and there is no treatment available to restore them. These myelinating cells--called oligodendrocytes--are critical for shielding and repairing the brain's neurons throughout life.

A team led by neurosurgeon Viviane Tabar, MD, and research associate Jinghua Piao, PhD, of the Memorial Sloan Kettering Cancer Center in New York City, wondered whether stem cells could be coaxed to replace these lost oligodendrocyte progenitor cells. They found that this could be achieved by growing stem cells--either human embryonic stem cells or induced pluripotent stem cells derived from skin biopsies--in the presence of certain growth factors and other molecules.

Next, the investigators used the lab-grown oligodentrocyte progenitor cells to treat rats that had been exposed to brain irradiation. When the cells were injected into certain regions of the brain, brain repair was evident, and rats regained the cognitive and motor skills that they had lost due to radiation exposure. The treatment also appeared to be safe: none of the animals developed tumors or inappropriate cell types in the brain.

"Being able to repair radiation damage could imply two important things: improving the quality of life of survivors and potentially expanding the therapeutic window of radiation," said Dr. Tabar. "This will have to be proven further, but if we can repair the brain effectively, we could be bolder with our radiation dosing, within limits." This could be especially important in children, for whom physicians deliberately deliver lower radiation doses.

Story Source:

The above story is based on materials provided by Cell Press. Note: Materials may be edited for content and length.

View original post here:
Human stem cells repair damage caused by radiation therapy for brain cancer in rats

The Hormel Institute has announced Rebecca Morris, leader of the Stem Cells and Cancer research section, has received a one-year, $100,000 grant from the Minnesota Chemoprevention Consortium to study bone marrow-derived cells as potential new targets for preventing skin cancer.

The consortium includes the University of Minnesota's Hormel Institute, Mayo Clinic, the U of M's Masonic Cancer Center and Hormel Foods Consortium. The consortium goes by the moniker "MC^2."

An online service is needed to view this article in its entirety. You need an online service to view this article in its entirety.

Need an account? Create one now.

kAmQ%96 |r/a C6D62C49 C6=2E6D E@ 2?@E96C AC@;64E =65 3J sC] |@CC:D E92E 92D 366? ECJ:?8 E@ 56E6C>:?6 H96E96C 3@?6 >2CC@H56C:G65 46==D A=2J 2 C@=6 😕 3C62DE 42?46Cj E92E H@C< 92D 366? 7F?565 3J 5@?2E:@?D C2:D65 E9C@F89 pFDE:?VD 2??F2= V!2:?E E96 %@H? !:?6= x?DE:EFE6 AC6DD C6=62D6]k^Am

kAmw@C>6= x?DE:EFE6 H2D 7@F?565 😕 `hca 3J y2J r] w@C>6= 2D A2CE @7 E96 & @7 | 8C25F2E6 D49@@=]k^Am

kAmxE 92D 364@>6 2 =625:?8 42?46CAC6G6?E:@?[ @C 496>@AC6G6?E:@?[ C6D62C49 724:=:EJ[ H:E9 >F=E:A=6 6IA2?D:@? 2E :ED pFDE:? =@42E:@?[ g_` `eE9 pG6] }t] #6D62C49 DEF5:6D 92G6 AC@5F465 52E2 762EFC65 😕 >2;@C D4:6?E:7:4 ;@FC?2=D[ DF49 2D r2?46C !C6G6?E:@? #6D62C49[ r6== #6A@CED[ tq:@|65:4:?6[ ~?4@D4:6?46 2?5 }2EFC6]k^Am

kAm%96 AC@;64ED F?56CE2<6? 3J |@CC:D 2C6 4@?D:56C65 3J w@C>6= x?DE:EFE6 2D 2 DE6A E@H2C5 2AA=J:?8 7@C 255:E:@?2= >2;@C 7656C2= C6D62C49 8C2?5D[ E96 AC6DD C6=62D6 D2JD] k6>my677 w2?D6=k^6>mk^Am

More:
Heard on the Street: Hormel Institute staffer gets $100,000 for cancer research

TORONTO Two Canadian research centres are gearing up for a clinical trial to determine if a type of stem cell can help alleviate the symptoms of multiple sclerosis.

Researchers at the Ottawa Hospital and Winnipegs Health Sciences Centre will each recruit 20 MS patients for the trial that will test whether mesenchymal stem cells can reduce inflammation and even help repair damage already caused by the disease.

MS is thought to be an autoimmune disease that creates inflammation in the central nervous system, resulting in injury to myelin, the protective sheath that covers nerves. This damage can create a host of symptoms, leading to varying degrees of physical disability and cognitive impairment.

Mesenchymal stem cells, which are found in bone marrow, fat, skin tissue and umbilical cord blood, have the ability to modify the immune system and reduce inflammation, said neurologist Dr. Mark Freedman of the Ottawa Hospital Research Institute, who is leading the clinical trial.

Freedman said researchers want to determine if these stem cells can demonstrate anti-inflammatory properties in patients with MS.

But thats not why were doing it, he said of the study, called MESCAMS (MEsenchymal Stem cell therapy for CAnadian MS patients). We have lots of drugs that can control inflammation in multiple sclerosis thats what all the new medicines do.

The ultimate hope is that we will be able to exploit some of their other very important biological properties, which is to promote repair.

The two research centres are ready to begin enrolling patients for the trial, which has specific acceptance criteria. While most of those accepted will likely have the relapsing-remitting form of the disease, Freedman said some people with more severe primary- or secondary-progressive MS may also be eligible if they fit the criteria.

The study protocol can be accessed at http://www.clinicaltrials.gov/show/NCT02239393. It will later be posted on the website of the MS Society of Canada, which along with the Multiple Sclerosis Scientific Research Foundation has provided a $4.2-million grant for the study.

To conduct the trial, half the patients will be randomly assigned to receive their own mesenchymal stem cells within weeks of them being extracted from the bone marrow and grown in the lab; the remainder of the participants will instead be infused with a mock stem-cell solution, and wont receive their actual stem cells for about six months. The two groups will then be compared.

Here is the original post:
Trial to test stem cells in MS patients

For the first time, researchers have been able to use pluripotent stem cells to generate cells that can grow new hair.

Hair growing on hairless mice thanks to induced pluripotent stem cells. Sanford-Burnham Medical Research Institute

It's been theorised for years, but now human stem cells have resulted in hair growth for the very first time.

"We have developed a method using human pluripotent stem cells to create new cells capable of initiating human hair growth. The method is a marked improvement over current methods that rely on transplanting existing hair follicles from one part of the head to another," said Alexey Terskikh, Ph.D., associate professor in the Development, Aging and Regeneration Program at Sanford-Burnham.

"Our stem cell method provides an unlimited source of cells from the patient for transplantation and isn't limited by the availability of existing hair follicles."

The process started with human pluripotent embryonic stem cells -- that is, stem cells that are capable of developing into any other cell -- which were then developed into neural crest cells. These are cells that can develop into a variety of cells on the head, including brain cells, cartilage, bone and muscle cells.

From the neural crest cell point, the team coaxed the cells to grow into dermal papillae cells, the cells that nourish the skin and regulate follicle growth and formation. When transplanted -- in the case of this study, into hairless mice -- these cells flourish.

Another part of the study examined whether the same result could be achieved using dermal papillae cells taken from the scalps of adult humans. Outside the body, living in culture, these cells are not suitable for hair transplants, since they lost their ability to induce follicle formation. The number of hairs their produced was insignificant.

"In adults, dermal papilla cells cannot be readily amplified outside of the body and they quickly lose their hair-inducing properties," said Terskikh. "We developed a protocol to drive human pluripotent stem cells to differentiate into dermal papilla cells and confirmed their ability to induce hair growth when transplanted into mice."

The researchers say that their research represents the first step towards a cell-based treatment for hair loss, which affects 40 million men and 21 million women in the United States.

Read more from the original source:
Stem cell-grown hair could help those with hair loss

A way to eradicate cancer stem cells, using the side-effects of commonly used antibiotics, has been discovered by a University of Manchester researcher following a conversation with his young daughter.

Professor Michael P. Lisanti, Director of the Breakthrough Breast Cancer Unit, led the research. He was inspired to look at the effects of antibiotics on the mitochondria of cancer stem cells by a conversation with his daughter Camilla about his work at the University's Institute of Cancer Sciences.

His new paper, published in Oncotarget, opens up the possibility of a treatment for cancer, which is highly effective and repurposes drugs which have been safely used for decades.

Mitochondria are the 'engine' parts of the cells and are the source of energy for the stem cells as they mutate and divide to cause tumours. Cancer stem cells are strongly associated with the growth and recurrence of all cancers and are especially difficult to eradicate with normal treatment, which also leads to tumours developing resistance to other types of therapy.

Professor Lisanti said: "I was having a conversation with Camilla about how to cure cancer and she asked why don't we just use antibiotics like we do for other illnesses. I knew that antibiotics can affect mitochondria and I've been doing a lot of work recently on how important they are to the growth of tumours, but this conversation helped me to make a direct link."

Professor Lisanti worked with colleagues from The Albert Einstein College of Medicine, New York and the Kimmel Cancer Centre, Philadelphia. The team used five types of antibiotics -- including one used to treat acne (doxycycline) -- on cell lines of eight different types of tumour and found that four of them eradicated the cancer stem cells in every test. This included glioblastoma, the most aggressive of brain tumours, as well as lung, prostate, ovarian, breast, pancreatic and skin cancer.

Mitochondria are believed to be descended from bacteria which joined with cells early on in the evolution of life. This is why some of the antibiotics which are used to destroy bacteria also affect mitochondria, though not to an extent which is dangerous to people. When they are present in stem cells, mitochondria provide energy for growth and, crucially, for division, and it is this process going wrong which leads to cancer.

In the lab, the antibiotics had no harmful effect on normal cells, and since they are already approved for use in humans, trials of new treatments should be simpler than with new drugs -- saving time and money.

Professor Lisanti said: "This research makes a strong case for opening new trials in humans for using antibiotics to fight cancer. Many of the drugs we used were extremely effective, there was little or no damage to normal cells and these antibiotics have been in use for decades and are already approved by the FDA for use in humans. However, of course, further studies are needed to validate their efficacy, especially in combination with more conventional therapies."

Dr Matthew Lam, Senior Research Officer at Breakthrough Breast Cancer, said: "The conclusions that the researchers have drawn, whilst just hypotheses at this stage, are certainly interesting. Antibiotics are cheap and readily available and if in time the link between their use and the eradication of cancer stem cells can be proved, this work may be the first step towards a new avenue for cancer treatment.

Visit link:
Antibiotics as new cancer treatments? Conversation with schoolgirl sparks idea

Professor Michael P. Lisanti, Director of the Breakthrough Breast Cancer Unit, led the research. He was inspired to look at the effects of antibiotics on the mitochondria of cancer stem cells by a conversation with his daughter Camilla about his work at the University's Institute of Cancer Sciences.

His new paper, published in Oncotarget, opens up the possibility of a treatment for cancer, which is highly effective and repurposes drugs which have been safely used for decades.

Mitochondria are the 'engine' parts of the cells and are the source of energy for the stem cells as they mutate and divide to cause tumours. Cancer stem cells are strongly associated with the growth and recurrence of all cancers and are especially difficult to eradicate with normal treatment, which also leads to tumours developing resistance to other types of therapy.

Professor Lisanti said: "I was having a conversation with Camilla about how to cure cancer and she asked why don't we just use antibiotics like we do for other illnesses. I knew that antibiotics can affect mitochondria and I've been doing a lot of work recently on how important they are to the growth of tumours, but this conversation helped me to make a direct link."

Professor Lisanti worked with colleagues from The Albert Einstein College of Medicine, New York and the Kimmel Cancer Centre, Philadelphia. The team used five types of antibiotics - including one used to treat acne (doxycycline) - on cell lines of eight different types of tumour and found that four of them eradicated the cancer stem cells in every test. This included glioblastoma, the most aggressive of brain tumours, as well as lung, prostate, ovarian, breast, pancreatic and skin cancer.

Mitochondria are believed to be descended from bacteria which joined with cells early on in the evolution of life. This is why some of the antibiotics which are used to destroy bacteria also affect mitochondria, though not to an extent which is dangerous to people. When they are present in stem cells, mitochondria provide energy for growth and, crucially, for division, and it is this process going wrong which leads to cancer.

In the lab, the antibiotics had no harmful effect on normal cells, and since they are already approved for use in humans, trials of new treatments should be simpler than with new drugs - saving time and money.

Professor Lisanti said: "This research makes a strong case for opening new trials in humans for using antibiotics to fight cancer. Many of the drugs we used were extremely effective, there was little or no damage to normal cells and these antibiotics have been in use for decades and are already approved by the FDA for use in humans. However, of course, further studies are needed to validate their efficacy, especially in combination with more conventional therapies."

Dr Matthew Lam, Senior Research Officer at Breakthrough Breast Cancer, said: "The conclusions that the researchers have drawn, whilst just hypotheses at this stage, are certainly interesting. Antibiotics are cheap and readily available and if in time the link between their use and the eradication of cancer stem cells can be proved, this work may be the first step towards a new avenue for cancer treatment.

"This is a perfect example of why it is so important to continue to invest in scientific research. Sometimes there are answers to some of the biggest questions right in front of us but without ongoing commitment to the search for these answers, we'd never find them."

Originally posted here:
Schoolgirl comment points to antibiotics as new cancer treatments

Achievementmade after coaxing stem cells to become papilla cells Dermal papilla is a special type of cell which is vital to follicle formation It could provide an unlimited source of cells for hair transplant procedures

By Ellie Zolfagharifard For Dailymail.com

Published: 14:15 EST, 27 January 2015 | Updated: 16:16 EST, 27 January 2015

52 shares

33

View comments

Finding a cure for baldness has become the holy grail for scientists the world over.

Now researchers in Orlando have come a step closer to a natural treatment after successfully growing new hair using human stem cells.

The breakthrough was achieved after coaxing stem cells to become dermal papilla cells a special type of cell which is vital to follicle formation.

Researchers in Orlando have come a step closer to a natural treatment for baldness after successfully growing new hair using human stem cells. Pictured is the hair growth on the leg of an adult rat

Continued here:
A cure for hair loss? Scientists grow hair on rats using stem cells - and they say the treatment could work on humans ...

LOS ANGELES (Jan. 27, 2015) - Researchers in the Cedars-Sinai Board of Governors Regenerative Medicine Institute have devised a novel way to generate transplantable corneal stem cells that may eventually benefit patients suffering from life-altering forms of blindness.

Scientists used human corneal cells to generate pluripotent stem cells that have a capacity to become virtually any body cell. Then, putting these cells on natural scaffolds, researcher's facilitated differentiation of these stem cells back to corneal cells.

"Our research shows that cells derived from corneal stem cells are attractive candidates for generating corneal cells in the laboratory," said Alexander Ljubimov, PhD, director of the Eye Program at the Board of Governors Regenerative Medicine Institute and principal investigator on this research study.

This research, published in the journal Stem Cells Translational Medicine, marks an important first step toward creating a bank of corneal stem cells that may potentially benefit patients who suffer from many forms of corneal blindness. The group is now working to optimize the process with National Institutes of Health funding.

Corneal deficiencies may have genetic or inflammatory roots or be caused by injuries, like burns to the skin in occupational accidents. They result in damage or death of stem cells that renew the outermost part of the cornea. If left untreated, they often cause compromised vision or blindness.

Over 150,000 Americans and more than 3 million individuals worldwide are affected by corneal blindness.

###

Study collaborators include Clive Svendsen, PhD, director of the Board of Governors Regenerative Medicine Institute and professor of biomedical sciences and medicine; Dhruv Sareen, PhD, director of the Induced Pluripotent Stem Cell Core and assistant professor of biomedical sciences; Mehrnoosh Saghizadeh, PhD, assistant professor of biomedical sciences; Yaron Rabinowitz, MD, director of the Division of Ophthalmology Research; and Vincent A. Funari, PhD, director of the Genomics Core and assistant professor of pediatrics.

Citation: Sareen D, Saghizadeh M, Ornelas L, et al. Differentiation of human limbal-derived induced pluripotent stem cells into limbal-like epithelium. Stem Cells Transl Med. 2014; 3(9):1002-12.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read the rest here:
Researchers advance the science behind treating patients with corneal blindness

Hair growing from human dermal papillae cells, which were cultivated from pluripotent stem cells.

Cells needed to grow hair have been produced from human stem cells, according to a study led by scientists at the Sanford-Burnham Medical Research Institute in La Jolla. The first-time feat could uncork a bottleneck in developing hair-replacement therapies, the scientists say.

Called the dermal papillae, these cells regulate hair follicle formation and growth cycles. They rapidly lose their hair-generating ability after being grown outside the body, limiting their use for hair regrowth. Another cell type derived from stem cells effectively substitutes for the dermal papillae, the scientists found.

These artificial dermal papillae cells were grown from pluripotent stem cells, which can be derived either from human embryos or a patient's own skin cells. The latter, called induced pluripotent stem cells, are of the most interest, said lead researcher Alexey V. Terskikh. Patients can donate their own IPS cells, which can be grown into the replacement dermal papillae in "unlimited" quantities," he said.

Alexey V. Terskikh, Principal Investigator, Sanford-Burnham Medical Research Institute / Sanford-Burnham Medical Research Institute

Sanford-Burnham is now looking for business partners to commercialize the discovery. More information can be found at: utsandiego.com/sbhair.

The study was published last week in the journal PLOS One. Terskikh is the study's senior author. Ksenia Gnedeva is first author.

In the lab, the human embryonic stem cells were first turned into neural crest cells, which produce brain cells, cartilage, bone, pigment and muscle cells. The cells were then converted into the artificial dermal papillae cells. These human cells induced hair formation, when transplanted along with mouse skin epidermal cells into immune-deficient and nearly hairless "nude mice".

Because nude mice were created from albino ancestors, the transplanted skin cells were chosen from dark-haired mice. This let the scientists distinguish hairs grown by the mice from cells grown by the transplanted cells.

Transplanted epidermal cells alone caused "minimal" growth, the study said.

Continue reading here:
Sanford-Burnham's hair-raising study

ELK GROVE (CBS13) Hes only 17, but hes already making big waves in the science community.

A local high school senior was selected as a semi-finalist in the 2015 Intel Science Talent Search. His research on stem cells set him apart from the rest. Out of hundreds of applicants, Ryan Fong, a senior at Sheldon High School in Elk Grove, is being recognized for his research in stem cells. Its an opportunity he says he wont soon forget.

Each of these cells is genetic material from one cell, he explains.

He doesnt come from a line of doctors or medical researchers. Fong is just a teenager interested in stem cells.

Its such a young field and it holds so much potential to redefine what we think is medically possible, he says.

Fong wasnt always intrigued by science, but a couple of years ago, at the request of a teacher, he decided to enter the Teen Biotech Challenge and happened to win an internship at the UC Davis School of Medicine.

I didnt know anything about research and I didnt know what I was getting into, but I dived in head first, said Fong.

That internship became a launching pad for Fong. He was published in a medical peer review journal called Stem Cells. And this past summer, he spent his time in Stanford among doctors and researchers working on reprogramming cells from a layer of skin so that it can match any cell type in the body.

So were taking someones cells from their skin and turning them into cells that can be found in the lungs, said Fong.

Their research on the topic won Fong a spot as a semi-finalist in the 2015 Intel Science Talent Search, and a $1,000 scholarship.

Read more from the original source:
Local Teen Selected As Semi-Finalist In Intel Science Talent Search

A new procedure can quickly and efficiently increase the length of human telomeres, the protective caps on the ends of chromosomes that are linked to aging and disease, according to scientists at the Stanford University School of Medicine.

Treated cells behave as if they are much younger than untreated cells, multiplying with abandon in the laboratory dish rather than stagnating or dying.

The procedure, which involves the use of a modified type of RNA, will improve the ability of researchers to generate large numbers of cells for study or drug development, the scientists say. Skin cells with telomeres lengthened by the procedure were able to divide up to 40 more times than untreated cells. The research may point to new ways to treat diseases caused by shortened telomeres.

Telomeres are the protective caps on the ends of the strands of DNA called chromosomes, which house our genomes. In young humans, telomeres are about 8,000-10,000 nucleotides long. They shorten with each cell division, however, and when they reach a critical length the cell stops dividing or dies. This internal "clock" makes it difficult to keep most cells growing in a laboratory for more than a few cell doublings.

'Turning back the internal clock'

"Now we have found a way to lengthen human telomeres by as much as 1,000 nucleotides, turning back the internal clock in these cells by the equivalent of many years of human life," said Helen Blau, PhD, professor of microbiology and immunology at Stanford and director of the university's Baxter Laboratory for Stem Cell Biology. "This greatly increases the number of cells available for studies such as drug testing or disease modeling."

A paper describing the research was published today in the FASEB Journal. Blau, who also holds the Donald E. and Delia B. Baxter Professorship, is the senior author. Postdoctoral scholar John Ramunas, PhD, of Stanford shares lead authorship with Eduard Yakubov, PhD, of the Houston Methodist Research Institute.

The researchers used modified messenger RNA to extend the telomeres. RNA carries instructions from genes in the DNA to the cell's protein-making factories. The RNA used in this experiment contained the coding sequence for TERT, the active component of a naturally occurring enzyme called telomerase. Telomerase is expressed by stem cells, including those that give rise to sperm and egg cells, to ensure that the telomeres of these cells stay in tip-top shape for the next generation. Most other types of cells, however, express very low levels of telomerase.

Transient effect an advantage

The newly developed technique has an important advantage over other potential methods: It's temporary. The modified RNA is designed to reduce the cell's immune response to the treatment and allow the TERT-encoding message to stick around a bit longer than an unmodified message would. But it dissipates and is gone within about 48 hours. After that time, the newly lengthened telomeres begin to progressively shorten again with each cell division.

Original post:
Telomere extension turns back aging clock in cultured human cells, Stanford study finds

20 hours ago

Transcription factor Twist1 is involved in many processes where cells change shape or function. Thereby, Twist1 is crucial for embryonic development, but has also been implicated in cancer progression. However, the precise contribution of Twist1 to these processes is under much debate. Scientists from the Helmholtz Zentrum Mnchen describe a new mode of action: a short-term, transient activation of Twist1 primes cells for stem cell-like properties. By contrast, prolonged, chronic Twist1 activity suppresses stem cell-like traits. These results, published in the journal Cell Reports, help to unravel seemingly contradictory observations and illuminate the complexities of transcription factor action in regeneration and tumor progression.

Team leader Christina Scheel summarizes the results: "Twist1 is a developmental master regulator that has also been implicated in cancer progression. We show that transient Twist1 activation primes certain cells for stem-cell-like properties and cellular plasticity. Said differently, induction of these traits depends on Twist1, but they are only displayed by the cells after Twist1 deactivation. By contrast, chronic Twist1 activity suppresses stem-cell-like properties and promotes a phenotype that is characterized by extreme changes in cell shape and function, effectively locking the cells into an invasive, non-proliferative phenotype. Thereby, our results provide an integrative view of seemingly contradictory results concerning the effects of Twist1 in physiological and pathological processes."

Duration of Twist1 activity decisive

Scientists from the Institute of Stem Cell Research and the Institute of Experimental Genetics at the Helmholtz Zentrum Mnchen (HMGU) examined the effects of Twist1 activation on breast epithelial cells, paying particular attention to the duration of the Twist1-signal. To their surprise, cells were permanently altered after a short dose of Twist1-activation: they proliferated under very stringent conditions usually permissive only for stem cells and were able to generate complex multicellular structures, suggesting a gain of cellular plasticity.

Twist1 may fuel regeneration

A high level of plasticity implies regenerative potential. However, when activated during tumor development, Twist1 promotes aggressive behaviour in tumor cells. With their investigations, the team was able to reveal a new aspect of how Twist1 regulates cell shape and function and, thereby, impacts regeneration, but also tumor progression.

"Our results offer important insights for further mechanistic studies of regeneration in healthy and tumour cells", explains first author Johanna Schmidt. "The precise delineation of the different modes of action by Twist1 provide the basis for future studies aiming to manipulate its activity either to promote regeneration or target advanced tumors ," adds co-author Elena Panzilius.

Explore further: New mechanism involved in skin cancer initiation, growth and progression

More information: Schmidt, J. et al. (2015), Stem-Cell-like Properties and Epithelial Plasticity Arise as Stable Traits after Transient Twist1 Activation, Cell Reports, DOI: 10.1016/j.celrep.2014.12.032

See original here:
Twist1: Complex regulator of cell shape and function

(Tokyo-AFP) - Japanese scientists say they are on their way to being able to create custom-made skin, bone and joints using a 3D printer.

Several groups of researchers around the world have developed small masses of tissue for implants, but now they are looking to take the next step and make them functional.

Tsuyoshi Takato, a professor at the University of Tokyo Hospital, said his team had been working to create "a next-generation bio 3D printer", which would build up thin layers of biomaterials to form custom-made parts.

His team combines stem cells -- the proto-cells that are able to develop into any body part -- and proteins that trigger growth, as well as synthetic substance similar to human collagen.

Using a 3D printer, they are working on "mimicking the structure of organs" -- such as the hard surface and spongy inside for bones, Takato said.

In just a few hours, the printer crafts an implant using data from a Computer Tomography (CT) scan.

These implants can fit neatly into place in the body, and can quickly become assimilated by real tissue and other organs in the patient, the plastic surgeon said.

"We usually take cartilage or bone from the patient's own body (for regular implants), but these custom-made implants will mean not having to remove source material," Takato said.

The technology could also offer hope for children born with bone or cartilage problems, for whom regular synthetic implants are no good because of the rate of their body's growth.

The main hurdle was the heat generated by conventional 3D printers, which damages living cells and protein.

Read the original post:
Japan researchers target 3D-printed body parts

(MENAFN - The Peninsula) Japanese scientists say they are on their way to being able to create custom-made skin, bone and joints using a 3D printer.

Several groups of researchers around the world have developed small masses of tissue for implants, but now they are looking to take the next step and make them functional.

Tsuyoshi Takato, a professor at the University of Tokyo Hospital, said his team had been working to create "a next-generation bio 3D printer", which would build up thin layers of biomaterials to form custom-made parts.

His team combines stem cells - the proto-cells that are able to develop into any body part - and proteins that trigger growth, as well as synthetic substance similar to human collagen.

Using a 3D printer, they are working on "mimicking the structure of organs" - such as the hard surface and spongy inside for bones, Takato said.

In just a few hours, the printer crafts an implant using data from a Computer Tomography (CT) scan. These implants can fit neatly into place in the body, and can quickly become assimilated by real tissue and other organs in the patient, the plastic surgeon said.

"We usually take cartilage or bone from the patient's own body (for regular implants), but these custom-made implants will mean not having to remove source material," Takato said.

The technology could also offer hope for children born with bone or cartilage problems, for whom regular synthetic implants are no good because of the rate of their body's growth. The main hurdle was the heat generated by conventional 3D printers, which damages living cells and protein.

"We haven't fully worked out how to avoid heat denaturation but we already have some models and are exploring which offers the most efficient method," he said.

The artificial protein Takato and his team use was developed by Fujifilm, which has been studying collagen used in photographic films. Since it is modelled on human collagen and does not derive from animals, it can be easily assimilated in human bodies, reducing the risk of infections such as mad-cow disease.

See the rest here:
Japan scientists target 3D-printed body parts

FRESNO, Calif. (KFSN) --

Our bodies contain 23 pairs of them, 46 total. But if chromosomesare damaged, they can cause birth defects, disabilities, growth problems, even death.

Case Western scientist Anthony Wynshaw-Boris is studying how to repair damaged chromosomes with the help of a recent discovery. He's taking skin cells and reprogramming them to work like embryonic stem cells, which can grow into different cell types.

"You're taking adult or a child's skin cells. You're not causing any loss of an embryo, and you're taking those skin cells to make a stem cell." Anthony Wynshaw-Boris, M.D., PhD, of Case Western Reserve University, School of Medicine told ABC30.

Scientists studied patients with a specific defective chromosome that was shaped like a ring. They took the patients' skin cells andreprogrammed them into embryonic-like cells in the lab. They found this process caused the damaged "ring" chromosomes to be replaced by normal chromosomes.

"It at least raises the possibility that ring chromosomes will be lost in stem cells," said Dr. Wynshaw-Boris.

While this research was only conducted in lab cultures on the rare ring-shaped chromosomes, scientists hope it will work in patients with common abnormalities like Down syndrome.

"What we're hoping happens is we might be able to use, modify, what we did, to rescue cell lines from any patient that has any severe chromosome defect," Dr. Wynshaw-Boris explained.

It's research that could one day repair faulty chromosomes and stop genetic diseases in their tracks.

The reprogramming technique that transforms skin cells to stem cells was so ground-breaking that a Japanese physician won the Nobel Prize in medicine in 2012 for developing it.

Go here to read the rest:
Stem Cells to Repair Broken Chromosomes: Medicine's Next Big Thing?

Researchers have successfully improved the ability of muscle to repair itself - by artificially increasing levels of the BMI1 gene in the muscle-specific stem cells of mice with muscular dystrophy.

The BMI1 gene has been previously linked to the body's ability to regenerate tissue cells in areas such as blood or skin.

Led by Queen Mary University of London and published in the Journal of Experimental Medicine, the study provides the first proof of concept that manipulating the activity of this gene enhances the regeneration of the dystrophic muscle to a level where strength is visibly improved. For example, the mice were able to run on a treadmill for a longer time period and at a faster pace.

This line of research will now be further developed and scientists aim to one day apply the treatment to patients with chronic muscle wasting such as muscular dystrophy.

Muscular dystrophy is a devastating and incurable condition. Duchenne Muscular Dystrophy - the deadliest form of the muscle-wasting disease - is caused by mutations in a gene which eventually cause muscle fibres to become damaged and waste away.

Duchenne Muscular Dystrophy is characterised by repeated cycles of muscle damage and repair, resulting in exhaustion of the muscle repair cells. It affects one in 3,500 boys and normally proves fatal by early adulthood.

Professor Silvia Marino, Lead Author, Queen Mary University of London, comments: "This study has given us the first 'proof of concept' that harnessing the gene BMI1 can significantly enhance the regeneration of dystrophic muscles to a level where strength is visibly improved. We plan to continue our research and hope to establish whether this concept can be successfully applied to patients with muscular dystrophy, but possibly other degenerative conditions or even traumatic muscle damage."

###

This research was funded by the MRC and the charity Muscular Dystrophy Campaign.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read more here:
Hope for muscular dystrophy patients: Harnessing gene helps repair muscle damage

Squamous cell carcinoma (SCC) represents the second most frequent skin cancer with more than half million new patients affected every year in the world. Cancer stem cells (CSCs) are a population of cancer cells that have been described in many different cancers, including skin SCCs and that feed tumor growth, could be resistant to therapy thus being responsible for tumor relapse after therapy. However, still very little is known about the mechanisms that regulate CSCs functions.

In a new study published and making the cover of Cell Stem Cell, researchers led by Pr. Cdric Blanpain, MD/PhD, professor and WELBIO investigator at the IRIBHM, Universit libre de Bruxelles, Belgium, report the mechanisms regulating the different functions of Twist1 controlling skin tumour initiation, cancer stem cell function and tumor progression.

Benjamin Beck and colleagues used state of the art genetic mouse models to dissect, the functional role and molecular mechanisms by which Twist1 controls tumor initiation, cancer stem cell function and tumor progression. In collaboration with Dr Sandrine Rorive and Pr Isabelle Salmon from the department of Pathology at the Erasme Hospital, ULB and the group of Jean-Christophe Marine (VIB, KUL Leuven), they demonstrated that while Twist1 is not expressed in the normal skin, Twist1 deletion prevents skin cancer formation demonstrating the essential role of Twist1 during tumorigenesis. "It was really surprising to observe the essential role of Twist1 at the earliest step of tumor formation, as Twist1 was thought to stimulate tumor progression and metastasis" comments Benjamin Beck, the first author of this study.

The authors demonstrate that different levels of Twist1 are necessary for tumor initiation and progression. Low level of Twist1 is required for the initiation of benign tumors, while higher level of Twist1 is necessary for tumor progression. They also demonstrate that Twist1 is essential for tumor maintenance and the regulation of cancer stem cell function. The researchers also uncovered that the different functions of Twist1 are regulated by different molecular mechanisms, and identified a p53 independent role of Twist1 in regulating cancer stem cell functions.

In conclusion, this work shows that Twist1, a well-known regulator of tumor progression, is necessary for tumor initiation, regulation of cancer stem cell function and malignant progression. "It was really interesting to see that different levels of Twist1 are required to carry out these different tumor functions and that these different Twist1 functions are regulated by different molecular pathways. Given the diversity of cancers expressing Twist1, the identification of the different mechanisms controlled by Twist1 are likely to be relevant for other cancers" comments Cdric Blanpain, the last and corresponding author of this study.

Story Source:

The above story is based on materials provided by Libre de Bruxelles, Universit. Note: Materials may be edited for content and length.

See the rest here:
Skin cancer: New mechanism involved in tumor initiation, growth and progression

Researchers at King's College London have identified a new mechanism by which skin damage triggers the formation of tumours, which could have important therapeutic implications for patients suffering with chronic ulcers or skin blistering diseases.

The study, published today in Nature Communications, highlights an innate sensing of bacteria by immune cells in the formation of skin tumours. This molecular process could tip the balance between normal wound repair and tumour formation in some patients, according to researchers.

Although an association between tissue damage, chronic inflammation and cancer is well established, little is known about the underlying cause. Epidermolysis Bullosa (EB), for instance, is one of several rare inherited skin conditions associated with chronic wounding and increased risk of tumours.

However, this study - funded primarily by the Medical Research Council (MRC) and the Wellcome Trust - is the first to demonstrate that bacteria present on the skin can contribute to the development of skin tumours.

Researchers found that when mice with chronic skin inflammation are wounded they develop tumours at the wound site, with cells of the immune system required for this process to take place. They discovered that the underlying signalling mechanism involves a bacterial protein, flagellin, which is recognised by a receptor (Toll-like receptor 5) on the surface of the immune cells.

Although the direct relevance to human tumours is yet to be tested, researchers have shown that a protein called HMGB1 - found to be highly expressed in mice with chronic skin inflammation - is increased in human patients with Epidermolysis Bullosa (EB). The study found a reduction in HMGB1 levels in mice when the TLR-5 receptor was removed from immune cells. This raises the possibility of future treatments aimed at reducing levels of the flagellin bacterial protein on the skin surface, or targeting the TLR-5 receptor.

Professor Fiona Watt, lead author and Director of the Centre for Stem Cells and Regenerative Medicine at King's College London, said: 'These findings have broad implications for various types of cancers and in particular for the treatment of tumours that arise in patients suffering from chronic ulcers or skin blistering diseases.

'In the context of chronic skin inflammation, the activity of a particular receptor in white blood cells, TLR-5, could tip the balance between normal wound repair and tumour formation.'

Professor Watt added: 'Our findings raise the possibility that the use of specific antibiotics targeting bacteria in wound-induced malignancies might present an interesting clinical avenue.'

###

Continued here:
Bacteria could contribute to development of wound-induced skin cancer

Fat cells shield against skin infections

(IANS) / 3 January 2015

For the study, the researchers exposed mice to Staphylococcus aureus, a common bacterium and major cause of skin and soft tissue infections in humans.

New York: Researchers have discovered that fat cells below the skin help protect you from bacteria.

These skin fat cells known as adipocytes produce antimicrobial peptides that help fend off invading bacteria and other pathogens, the findings showed, pointing to a previously unknown role for the dermal fat cells.

It was thought that once the skin barrier was broken, it was entirely the responsibility of circulating (white) blood cells like neutrophils and macrophages to protect us from getting sepsis, said principal investigator Richard Gallo, professor at University of California, San Diego School of Medicine.

But it takes time to recruit these cells (to the wound site). We now show that the fat stem cells are responsible for protecting us, Gallo added.

It was not known that adipocytes could produce antimicrobials, let alone that they make almost as much as a neutrophil, Gallo said.

For the study, the researchers exposed mice to Staphylococcus aureus, a common bacterium and major cause of skin and soft tissue infections in humans.

They detected a major increase in both the number and size of fat cells at the site of infection within hours.

Originally posted here:
Fat cells shield against skin infections

January 2, 2015

Credit: Thinkstock

Chuck Bednar for redOrbit.com Your Universe Online

Fat cells located beneath a persons skin could help protect them from bacterial infections, according to a new study published Thursday in the journal Science.

In the study, Dr. Richard Gallo, a professor and chief of dermatology at the University of California, San Diego School of Medicine, and his colleagues report that they had discovered a previously unknown function of these dermal fat cells, also known as adipocytes: they produce antimicrobial peptides that help combat bacteria and other types of pathogens.

It was thought that once the skin barrier was broken, it was entirely the responsibility of circulating (white) blood cells like neutrophils and macrophages to protect us from getting sepsis, explained Gallo. But it takes time to recruit these cells (to the wound site).

We now show that the fat stem cells are responsible for protecting us. That was totally unexpected, he added. It was not known that adipocytes could produce antimicrobials, let alone that they make almost as much as a neutrophil.

A persons body launches a complex, multi-tiered defense against microbial infection, the authors said. Several different types of cells are involved, and the process ends with the arrival of specialized cells known as neutrophils and monocytes that target and destroy pathogens.

Before any of that can happen, a more immediate response is required one that can counter the ability of pathogens to rapidly increase their numbers, however. That task is typically performed by epithelial cells, mast cells and leukocytes residing in the area of infection.

Previous research conducted in Gallos lab detected Staphylococcus aureus, a common type of bacteria and a major source of skin infection on humans, in the fat layer of the skin. Antibiotic-resistant forms of this bacterial have become a significant health issue throughout the world, so the study authors looked to see what role adipocytes played in preventing skin infections.

See the original post here:
Fat cells may actually not be so bad